Laboratory of Tumor Immunology and Biology and.
CCR Collaborative Bioinformatics Resource (CCBR), Center for Cancer Research, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
J Clin Invest. 2022 Apr 15;132(8). doi: 10.1172/JCI155148.
Collagens in the extracellular matrix (ECM) provide a physical barrier to tumor immune infiltration, while also acting as a ligand for immune inhibitory receptors. Transforming growth factor-β (TGF-β) is a key contributor to shaping the ECM by stimulating the production and remodeling of collagens. TGF-β activation signatures and collagen-rich environments have both been associated with T cell exclusion and lack of responses to immunotherapy. Here, we describe the effect of targeting collagens that signal through the inhibitory leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) in combination with blockade of TGF-β and programmed cell death ligand 1 (PD-L1). This approach remodeled the tumor collagenous matrix, enhanced tumor infiltration and activation of CD8+ T cells, and repolarized suppressive macrophage populations, resulting in high cure rates and long-term tumor-specific protection across murine models of colon and mammary carcinoma. The results highlight the advantage of direct targeting of ECM components in combination with immune checkpoint blockade therapy.
细胞外基质(ECM)中的胶原为肿瘤免疫浸润提供了物理屏障,同时也作为免疫抑制受体的配体发挥作用。转化生长因子-β(TGF-β)通过刺激胶原的产生和重塑,是塑造 ECM 的关键因素。TGF-β激活特征和富含胶原的环境都与 T 细胞排斥和对免疫治疗无反应有关。在这里,我们描述了靶向通过抑制性白细胞相关免疫球蛋白样受体-1(LAIR-1)信号的胶原与阻断 TGF-β和程序性细胞死亡配体 1(PD-L1)联合治疗的效果。这种方法重塑了肿瘤胶原基质,增强了 CD8+T 细胞的浸润和激活,并使抑制性巨噬细胞群重新极化,导致在结直肠癌和乳腺癌的小鼠模型中,治愈率高且具有长期的肿瘤特异性保护作用。这些结果突出了直接靶向 ECM 成分与免疫检查点阻断治疗相结合的优势。